Research on CAD-31 and Alzheimer’s Disease

Overview of the Study

In a 2017 study, researchers evaluated the effectiveness of CAD-31 in a mouse model of Alzheimer’s disease. The results indicate that CAD-31 shows promise as a treatment option for Alzheimer’s, successfully restoring declines in spatial memory, anxiety responses, and associative learning to normal levels.

Potential for a New Alzheimer’s Drug

Despite advancements in Alzheimer’s treatments, there are currently no medications available that can prevent brain cell death in patients affected by the disease. Two candidate drugs, J147 and its derivative CAD-31, have demonstrated potential in preventing Alzheimer’s in rodent models and promoting brain cell health in cell cultures. J147 has also been effective in reversing cognitive declines and alleviating some Alzheimer’s symptoms in older rats. However, further research is necessary to establish the efficacy of CAD-31 for treating Alzheimer’s in rodents and potentially in humans.

Recent Findings Published in Alzheimer’s Research & Therapy

A recent study published in *Alzheimer’s Research & Therapy* investigated the impact of CAD-31 on impairments associated with Alzheimer’s disease. The study involved ten-month-old female mice engineered to exhibit Alzheimer-like symptoms, alongside age-matched controls. Over three months, these mice were given diets supplemented with or without 10 mg/kg/day of CAD-31. The groups were categorized as control, control+31, AD (Alzheimer’s disease), and AD+31. Cognitive function was assessed, focusing on spatial memory, anxiety, and associative learning, before the mice were euthanized for blood and brain tissue sample collection.

Assessment of Spatial Memory

Spatial memory was evaluated using a two-day water maze test, where mice navigated to a platform within 180 seconds, aided by colored shapes on the pool walls. On the first day, four training trials were conducted with a visually-marked platform. The second day involved testing with an unmarked platform. The extra time taken to find the platform on day two was similar across control, control+31, and AD+31 mice, but significantly longer for AD mice, indicating that CAD-31 may rescue spatial memory declines associated with Alzheimer’s.

Evaluation of Anxiety Responses

To assess anxiety, an elevated plus-shaped maze was employed, consisting of two bright, open arms and two enclosed arms. Mice were allowed to acclimate in the center of the maze before freely moving between the arms for five minutes. The time spent in the open arms was recorded. Control, control+31, and AD+31 mice exhibited similar low times in the open arms, while AD mice spent significantly more time there, suggesting that CAD-31 can restore typical anxiety responses in these subjects.

Analysis of Associative Learning

Associative learning was tested using a two-day fear conditioning protocol, where mice associated a specific chamber with an unpleasant sensation, indicated by freezing behavior. On the first day, mice explored the chamber, followed by exposure to a tone and foot shock. On the second day, time spent frozen was recorded without the tone or shock. Control, control+31, and AD+31 mice showed similar freezing times, while AD mice demonstrated significantly less freezing, indicating that CAD-31 may help recover associative learning deficits linked to Alzheimer’s.

Comparison of CAD-31 and J147 in Cell Cultures

To compare the effectiveness of CAD-31 with J147, various doses of both compounds were applied to cell cultures reflecting age-related and Alzheimer-related declines in brain function. The potency was measured through the half-maximal effective concentration (EC50). The EC50 values were found to be 35nM for J147 and 18nM for CAD-31 in cortical cell cultures. For BDNF receptor-positive HT22 cells, the EC50s were 74nM for J147 and 95nM for CAD-31. The study also noted EC50 values for cells under different conditions, such as those deficient in antioxidants or exposed to amyloid beta plaques.

Gene Activity Changes Induced by CAD-31

RNA analysis of the samples revealed significant changes in gene activity. Control+31 mice exhibited 29 major changes compared to control mice, particularly related to synapse formation. In AD+31 mice, there were 730 major changes compared to AD mice, many linked to Alzheimer’s pathology, cell metabolism, and long-term potentiation. Notably, genes associated with reducing inflammation and enhancing nervous system health were more active in CAD-31 treated mice. The treatment also increased fatty acid metabolism in the brain.

Conclusions and Future Research Directions

The study concluded that CAD-31 is a promising candidate for treating Alzheimer’s disease, effectively restoring declines in spatial memory, behavioral responses, and associative learning in mice. It also protects against age-related and Alzheimer-related deficits in cell cultures while enhancing gene activity related to inflammation reduction and fatty acid metabolism. Future research should explore modifications to the AMPK cell signaling pathway, which may further enhance the anti-inflammatory and metabolic effects suggested by CAD-31’s activity in this study.

References

Written by Raishard Haynes, MBSDaugherty, D. et al. (2017). A novel Alzheimer’s disease drug candidate targeting inflammation and fatty acid metabolism. Alzheimer’s Research & Therapy, 9:50. DOI: 10.1186/s13195-017-0277-3.